Roswell Park

National Comprehensive Cancer Network Awards Champions for Excellence and Outstanding Contributions in Cancer Care

Retrieved on: 
星期三, 四月 17, 2024
Roswell Park, Cancer, NCCN, Person, Partner, Version 1, Risk, SARS-CoV-2, Health, Vaccination, Hematology, Uncertainty, ACCE, Partnership, Conference, Vaccine, Human, Friends, HERC, Patient, COVID-19, Treatment, MPH, Health equity, Caregiver, Committee, Infection, Diagnosis, Employment, Community

PLYMOUTH MEETING, Pa., April 17, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—is announcing 2024 award recipients that include individuals and groups who have made significant and noteworthy impacts on improving cancer care and supporting NCCN's mission to help all people with cancer to live better lives.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 17, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—is announcing 2024 award recipients that include individuals and groups who have made significant and noteworthy impacts on improving cancer care and supporting NCCN's mission to help all people with cancer to live better lives.
  • The committee is proud of its work in providing aggregated, streamlined, and actionable recommendations for COVID-19 vaccinations in persons with cancer."
  • The Partners in Cancer Care Award goes to people outside of NCCN Member Institutions who are instrumental in helping NCCN achieve its mission.
  • "All of this year's award recipients have demonstrated incredible leadership, commitment, and dedication in service to people with cancer everywhere.

Historic Opportunity to End Breast Cancer Launched Today

Retrieved on: 
星期二, 一月 30, 2024
Hope, Woman, Patient, Monroe Dunaway Anderson, Research, NBC News, Roswell Park, Cancer, Science, Friends, Survivor, Breast cancer, University, Vaccination, Immunotherapy, Recurrence, News, Dana–Farber Cancer Institute, Cleveland Clinic, Government, Vaccine, Immune system

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Today two high-profile breast cancer survivors, with the nation's top breast cancer doctors backing them, launched the Pink Eraser Project that will accelerate development of life saving breast cancer vaccines, aiming to shorten the process by 25 years.

Key Points: 
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Today two high-profile breast cancer survivors, with the nation's top breast cancer doctors backing them, launched the Pink Eraser Project that will accelerate development of life saving breast cancer vaccines, aiming to shorten the process by 25 years.
  • "The science to end breast cancer exists by harnessing the power of our own immune systems.
  • Dahlgren and Young, both breast cancer survivors, met when Dahlgren interviewed Young about her breast cancer journey and her quest to save women from the devastating disease effects.
  • "We are at a unique moment in time when the right collaboration and funding could mean breast cancer vaccines within a decade.

Adolescent and Young Adult (AYA) Cancer Experts Unite to Form First-of-its-Kind Consortium

Retrieved on: 
星期二, 一月 30, 2024
Adolescence, Health, Patient, Research, MD, Roswell Park, Knowledge, Survival, RWJBarnabas Health, Epidemiology, Consortium, University, Biomedical sciences, Oncology, Lymphoma, MBA, Cancer, Young adult, AYA, Cooper University Hospital, Master of Science, LRF, Diagnosis, Estate (law), Pharmaceutical industry

NEW YORK, Jan. 30, 2024 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) – the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – has announced the formation of its Adolescent and Young Adult (AYA) Lymphoma Consortium.

Key Points: 
  • In addition, the AYA Lymphoma Consortium and its membership will seek to support LRF's #EraseLymphoma initiative and raise awareness of the Foundation's AYA patient education efforts.
  • Both Dr. Evens and Dr. Kelly are globally recognized lymphoma researchers with a unique interest in the AYA patient population.
  • "There is a critical need to study lymphomas that occur in adolescents and young adults (AYA)," said Dr. Evens, co-chair of the AYA Lymphoma Consortium.
  • Other members of the AYA Lymphoma Consortium executive committee include pediatric oncologists, adult oncologists, laboratory and translational cancer researchers, epidemiologists, health services, survivorship, and quality of life experts from top institutions across the world.

Aster Insights, ORIEN to Present Abstract on Young Onset Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Retrieved on: 
星期二, 一月 16, 2024
Patient, Research, Incidence, Roswell Park, Female, ASCO, Male, Society, Data

TAMPA, Fla., Jan. 16, 2024 /PRNewswire/ -- Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced the company and members of the Oncology Research Information Exchange Network® (ORIEN) will be presenting at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held January 18-20, 2024 in San Francisco, CA.

Key Points: 
  • ORIEN researchers from Roswell Park Comprehensive Cancer Center will present an abstract titled, " Sex-based differences in the transcriptomic metabolic profiling in young onset colorectal cancer (YOCRC) " during the annual symposium.
  • Aster Insights and ten ORIEN® member institutions contributed to the research, which examines the differences in metabolic profiles between male and female patients with young onset colorectal cancer (YOCRC), compared with male and female patients with average onset colorectal cancer (AOCRC).
  • The abstract utilized patient data from Aster Avatar, the best-in-class, deepest multimodal dataset for discovery research in oncology.
  • "This research represents a years-long, collaborative effort across Aster Insights and ORIEN to better understand the unique biological differences in patients with young onset colorectal cancer, so that we can develop more effective, personalized treatments," said Dr. Sarbajit Mukherjee, gastrointestinal medical oncologist at Roswell Park Comprehensive Cancer Center, and the primary investigator of the study.

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer

Retrieved on: 
星期二, 十一月 14, 2023
CTL, AIM, Safety, NYSE, Senior, Breast cancer, Celecoxib, Roswell Park, Rintatolimod, Paper, Patient, TLR3, Journal, Immunology, CKM, Pembrolizumab, AIM ImmunoTech, Science of team science, Immunotherapy, Doctor of Philosophy, Manuscript, Pharmaceutical industry, Management, Cancer, MD

OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.

Key Points: 
  • OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.
  • The data were published in a manuscript titled, “ Systemic Infusion of TLR3-Ligand and IFNα in Breast Cancer Patients Reprograms Local Tumor Microenvironment for Selective CTL Influx ,” in The Journal for ImmunoTherapy of Cancer.
  • The pilot study evaluated the safety of systemic CKM composed of intravenous rintatolimod (Ampligen; selective TLR3 ligand), interferon α-2b and celecoxib, and the combination’s ability to promote local CTL influx to mTNBC lesions.
  • For more information about the study, please visit ClinicalTrials.gov: NCT03599453 .

The Inner Circle Acknowledges, Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology

Retrieved on: 
星期一, 十一月 13, 2023
Theta, Inner circle, Georgetown University, Brown University, Woman, Oncology nursing, Associate, Reproductive Sciences, Research, Radiation, Cervical cancer, Gynecologic Oncology (journal), Overlook Medical Center, Pathology, National Cancer Institute, Roswell Park, Mount Sinai School, Women's studies, Multimedia, Professional, Fellow, Thomas Jefferson University, Vaginal cancer, Medication, Health, Alpert Medical School, Vulvar cancer, ABOG, Uterine cancer, Exceptional Women in Publishing, Ovarian cancer, MD, Japanese Cancer Association, FACOG, Delta Sigma, Women's health, Atlantic Women's Colleges Conference, Carol, Volunteering, Flexner Report, Estate (law), Biology, Education, Birth control, Science, Gynaecology, Medicine, Cancer, New York (magazine), Neuroscience, Obstetrics

CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience, minoring in Women's Studies.
  • She then attended the Warren Alpert Medical School of Brown University for her medical degree, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health Systems Morristown and Overlook Medical Centers.

Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology Using Generative AI

Retrieved on: 
星期三, 十一月 1, 2023
Research, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Stem Cells, Other Technology, Health, Other Science, Chandos Chair of Medicine and Anatomy, FDA, CAR, CGMP, Associate, Ovarian cancer, Therapy, Roswell, II, Research and development, Translational research, Department of Medicine – University of Pamplona, Multimedia, Roswell Park Comprehensive Cancer Center, Senior, Alpha generation platform, Leukemia, Woman, Patient, Biomedicine, Lymphoma, Pharmaceutical industry, Roswell Park, Generate

In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.

Key Points: 
  • In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.
  • View the full release here: https://www.businesswire.com/news/home/20231101307318/en/
    Under the collaboration agreement, Generate:Biomedicines and Roswell Park will contribute toward creating optimized cell therapies, where a patient’s T cells are engineered to recognize and kill tumors.
  • The collaboration combines the programmability and scalability of The Generate Platform and Roswell Park’s expertise in cell therapy design, clinical development, and manufacturing to bring best-in-class cell therapies to patients.
  • It is anticipated that Roswell Park will serve as a site and recommend lead investigators for Phase I and II clinical trials.

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

Retrieved on: 
星期六, 十月 14, 2023
Multimedia, M&T Bank, Priority review, Cancer, Glomus tumor, Food, Doctor of Philosophy, Hope, Research, Roswell Park Comprehensive Cancer Center, Texas Oncology, Ride, Multiple myeloma, Roswell, MD, Fred Hutchinson Cancer Research Center, National Cancer Institute, University, Survival, Disease, FDA, Glioblastoma, Accelerated approval (FDA), Fast track (FDA), NDA, Neurosurgery, Overlook Medical Center, Northwell Health, Journal, FTD, Fast Track, Assistant, PSA, Regulation of tobacco by the U.S. Food and Drug Administration, American Journal of Clinical Oncology, Principal investigator, Prostate cancer, Brain, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical imaging, Medical device, Online shopping, DRS, Upstate New York, New York University, Roswell Park

BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The designation awarded to MimiVax Inc. provides more extensive and accelerated access to FDA resources for the company's development of the novel cancer immunotherapy SurVaxM, which is now in late-stage trials around the country.

Key Points: 
  • The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development of SurVaxM, which originated at Roswell Park.
  • BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).
  • From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide.
  • To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org , call 1-800-ROSWELL (1-800-767-9355) or email [email protected] .

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

Retrieved on: 
星期四, 十月 12, 2023
Priority review, Texas Oncology, UCSF, Fred Hutchinson Cancer Research Center, Disease, FDA, Science in newly industrialized countries, Accelerated approval (FDA), NDA, Overlook Medical Center, Journal, Northwell Health, FTD, Fast Track, NYU, American Journal of Clinical Oncology, Roswell Park, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical device, Glioblastoma

BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc. , a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).

Key Points: 
  • BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc. , a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).
  • MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma.
  • MimiVax is focused on completing the Phase 2b SURVIVE study and securing funding necessary to bring SurVaxM through the FDA approval process.
  • "The receipt of Fast Track Designation affirms the importance of new clinical developments of novel therapies to improve the treatment and outcomes for patients with newly diagnosed glioblastoma," said Michael Ciesielski, CEO of MimiVax.

AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

Retrieved on: 
星期五, 九月 22, 2023
Roswell Park Comprehensive Cancer Center, AIM, Non-governmental organization, Roswell Park, NYSE, International Collaboration for the Care of the Elderly, Pharmaceutical industry

OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023.

Key Points: 
  • OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023.
  • In addition to the presentation, the Company is proud to announce its sponsorship of the event.
  • Details for the presentation are as follows:
    Session: Session 7: Team Science: National and International Collaborations with NGOs, Academia, Pharma, & Biotech
    For more information about the conference, visit: https://www.roswellpark.org/msc-symposium .
  • The presentation will be available on the AIM website once presented at the conference.